We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
The Patented Medicine Prices Review Board (the Board) has ordered sanofi-aventis Canada Inc. (sanofi) to pay $9.4 million for excessive revenues relating to the sale of Penlac, a nail lacquer for treatment of a fungal infection of the nail
On January 20th the Supreme Court of Canada issued a decision which confirms the role of the Patented Medicine Prices Review Board (PMPRB) and the consumer protection purposes of ss
The Patented Medicine Prices Review Board is responsible for ensuring that patentees are not selling medicines at excessive prices in any market in Canada
